Alizapride
Chemical compound
- A03FA05 (WHO)
- In general: ℞ (Prescription only)
- N-[(1-Allylpyrrolidin-2-yl)methyl]-6-methoxy-1H-benzo[d][1,2,3]triazole-5-carboxamide
- 59338-93-1
Y
- 43008
- DB01425 Y
- 39202 Y
- P55703ZRZY
- D07102 Y
- ChEMBL290194 Y
- Interactive image
- C=CCN1CCCC1CNC(=O)c3cc2nn[nH]c2cc3OC
InChI
- InChI=1S/C16H21N5O2/c1-3-6-21-7-4-5-11(21)10-17-16(22)12-8-13-14(19-20-18-13)9-15(12)23-2/h3,8-9,11H,1,4-7,10H2,2H3,(H,17,22)(H,18,19,20)Y
- Key:KSEYRUGYKHXGFW-UHFFFAOYSA-NY
Alizapride (Litican, Plitican, Superan, Vergentan) is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. It is structurally related to metoclopramide and other benzamides.[1]
References
- ^ Ballatori E, Roila F (September 2003). "Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy". Health and Quality of Life Outcomes. 1: 46. doi:10.1186/1477-7525-1-46. PMC 212194. PMID 14521717.
- v
- t
- e
channel antagonists
receptor antagonists
(cannabinoids)
- Dronabinol
- Nabilone
- Tetrahydrocannabinol (cannabis)
(antihistamines)
(anticholinergics)
- Atropine
- Diphenhydramine
- Hydroxyzine (very mild)
- Hyoscyamine
- Scopolamine
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
